Your browser doesn't support javascript.
loading
IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients.
Mignot, Cyril; McMahon, Aoife C; Bar, Claire; Campeau, Philippe M; Davidson, Claire; Buratti, Julien; Nava, Caroline; Jacquemont, Marie-Line; Tallot, Marilyn; Milh, Mathieu; Edery, Patrick; Marzin, Pauline; Barcia, Giulia; Barnerias, Christine; Besmond, Claude; Bienvenu, Thierry; Bruel, Ange-Line; Brunga, Ledia; Ceulemans, Berten; Coubes, Christine; Cristancho, Ana G; Cunningham, Fiona; Dehouck, Marie-Bertille; Donner, Elizabeth J; Duban-Bedu, Bénédicte; Dubourg, Christèle; Gardella, Elena; Gauthier, Julie; Geneviève, David; Gobin-Limballe, Stéphanie; Goldberg, Ethan M; Hagebeuk, Eveline; Hamdan, Fadi F; Hancárová, Miroslava; Hubert, Laurence; Ioos, Christine; Ichikawa, Shoji; Janssens, Sandra; Journel, Hubert; Kaminska, Anna; Keren, Boris; Koopmans, Marije; Lacoste, Caroline; Lassuthová, Petra; Lederer, Damien; Lehalle, Daphné; Marjanovic, Dragan; Métreau, Julia; Michaud, Jacques L; Miller, Kathryn.
  • Mignot C; INSERM, U 1127, CNRS UMR 7225, Sorbonne Universites, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle epiniere, ICM, Paris, France. cyril.mignot@aphp.fr.
  • McMahon AC; APHP, Hôpital Pitie-Salpetriere, Departement de Genetique et de Cytogenetique; Centre de Reference Deficience Intellectuelle de Causes Rares; GRC UPMC «Deficience Intellectuelle et Autisme¼, Paris, France. cyril.mignot@aphp.fr.
  • Bar C; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Campeau PM; APHP, Reference Centre for Rare Epilepsies, Necker-Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.
  • Davidson C; INSERM U1163, Imagine Institute, Paris, France.
  • Buratti J; Paris Descartes University, Paris, France.
  • Nava C; Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and University of Montreal, Montreal, QC, Canada.
  • Jacquemont ML; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Tallot M; APHP, Hôpital Pitie-Salpetriere, Departement de Genetique et de Cytogenetique; Centre de Reference Deficience Intellectuelle de Causes Rares; GRC UPMC «Deficience Intellectuelle et Autisme¼, Paris, France.
  • Milh M; INSERM, U 1127, CNRS UMR 7225, Sorbonne Universites, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle epiniere, ICM, Paris, France.
  • Edery P; APHP, Hôpital Pitie-Salpetriere, Departement de Genetique et de Cytogenetique; Centre de Reference Deficience Intellectuelle de Causes Rares; GRC UPMC «Deficience Intellectuelle et Autisme¼, Paris, France.
  • Marzin P; CHU La Reunion-Groupe Hospitalier Sud Reunion, La Reunion, France.
  • Barcia G; CHU La Reunion-Groupe Hospitalier Sud Reunion, La Reunion, France.
  • Barnerias C; APHM, Hôpital d'Enfants de La Timone, Service de Neurologie Pediatrique, centre de reference deficiences intellectuelles de cause rare, Marseille, France.
  • Besmond C; Aix Marseille University, INSERM, MMG, UMR-S 1251, Faculte de medecine, Marseille, France.
  • Bienvenu T; Service de Genetique, Centre de Reference Anomalies du Developpement, Hospices Civils de Lyon, Bron, France.
  • Bruel AL; INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, GENDEV Team, Universite Claude Bernard Lyon 1, Bron, France.
  • Brunga L; Claude Bernard Lyon I University, Lyon, France.
  • Ceulemans B; APHP, Hôpital Pitie-Salpetriere, Departement de Genetique et de Cytogenetique; Centre de Reference Deficience Intellectuelle de Causes Rares; GRC UPMC «Deficience Intellectuelle et Autisme¼, Paris, France.
  • Coubes C; INSERM U1163, Imagine Institute, Paris, France.
  • Cristancho AG; Paris Descartes University, Paris, France.
  • Cunningham F; APHP, Service de genetique medicale, Necker-Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.
  • Dehouck MB; APHP, Unite fonctionnelle de Neurologie, Necker-Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.
  • Donner EJ; INSERM U1163, Imagine Institute, Paris, France.
  • Duban-Bedu B; Paris Descartes University, Paris, France.
  • Dubourg C; APHP, Laboratoire de Genetique et Biologie Moleculaires, Hôpital Cochin, HUPC, Paris, France.
  • Gardella E; Universite Paris Descartes Paris, Institut de Psychiatrie et de Neurosciences de Paris, Inserm U894, Paris, France.
  • Gauthier J; FHU-TRANSLAD, Universite de Bourgogne/CHU Dijon, Dijon, France.
  • Geneviève D; INSERM UMR 1231 GAD team, Genetics of Developmental disorders, Universite de Bourgogne-Franche Comte, Dijon, France.
  • Gobin-Limballe S; Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • Goldberg EM; Department of Pediatric Neurology, University Hospital and University of Antwerp, Antwerp, Belgium.
  • Hagebeuk E; Departement de Genetique Medicale, Maladies rares et Medecine Personnalisee, CHU de Montpellier, Montpellier, France.
  • Hamdan FF; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Hancárová M; European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Hubert L; Centre de Genetique Chromosomique, Hôpital St-Vincent-de-Paul, GHICL, Lille, France.
  • Ioos C; Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • Ichikawa S; Centre de Genetique Chromosomique, Hôpital St-Vincent-de-Paul, GHICL, Lille, France.
  • Janssens S; CHU Rennes, Service de Genetique Moleculaire et Genomique, Rennes, France.
  • Journel H; Danish Epilepsy Centre Filadelfia, Dianalund, Denmark.
  • Kaminska A; Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark.
  • Keren B; Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and University of Montreal, Montreal, QC, Canada.
  • Koopmans M; Departement de Genetique Medicale, Maladies rares et Medecine Personnalisee, CHU de Montpellier, Montpellier, France.
  • Lacoste C; INSERM U1183, Montpellier, France.
  • Lassuthová P; APHP, Service de genetique medicale, Necker-Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.
  • Lederer D; Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Lehalle D; Stichting Epilepsie Instellingen Nederland, SEIN, Zwolle, The Netherlands.
  • Marjanovic D; Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and University of Montreal, Montreal, QC, Canada.
  • Métreau J; Department of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
  • Michaud JL; INSERM U1163, Imagine Institute, Paris, France.
  • Miller K; Paris Descartes University, Paris, France.
Genet Med ; 21(4): 837-849, 2019 04.
Article en En | MEDLINE | ID: mdl-30206421
ABSTRACT

PURPOSE:

Variants in IQSEC2, escaping X inactivation, cause X-linked intellectual disability with frequent epilepsy in males and females. We aimed to investigate sex-specific differences.

METHODS:

We collected the data of 37 unpublished patients (18 males and 19 females) with IQSEC2 pathogenic variants and 5 individuals with variants of unknown significance and reviewed published variants. We compared variant types and phenotypes in males and females and performed an analysis of IQSEC2 isoforms.

RESULTS:

IQSEC2 pathogenic variants mainly led to premature truncation and were scattered throughout the longest brain-specific isoform, encoding the synaptic IQSEC2/BRAG1 protein. Variants occurred de novo in females but were either de novo (2/3) or inherited (1/3) in males, with missense variants being predominantly inherited. Developmental delay and intellectual disability were overall more severe in males than in females. Likewise, seizures were more frequently observed and intractable, and started earlier in males than in females. No correlation was observed between the age at seizure onset and severity of intellectual disability or resistance to antiepileptic treatments.

CONCLUSION:

This study provides a comprehensive overview of IQSEC2-related encephalopathy in males and females, and suggests that an accurate dosage of IQSEC2 at the synapse is crucial during normal brain development.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Convulsiones / Encefalopatías / Factores de Intercambio de Guanina Nucleótido / Discapacidad Intelectual Límite: Female / Humans / Infant / Male / Newborn Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Convulsiones / Encefalopatías / Factores de Intercambio de Guanina Nucleótido / Discapacidad Intelectual Límite: Female / Humans / Infant / Male / Newborn Idioma: En Año: 2019 Tipo del documento: Article